Cover Image
市場調查報告書

前列腺素D2受體2 (CD294, DP2, PTGDR2等) :開發中產品分析

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364835
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
前列腺素D2受體2 (CD294, DP2, PTGDR2等) :開發中產品分析 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 53 Pages
簡介

本報告提供以前列腺素D2受體2 (CD294, DP2, PTGDR2等) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

前列腺素D2受體2 (CD294, DP2, PTGDR2等)概要

治療藥的開發

前列腺素D2受體2 (CD294, DP2, PTGDR2等):開發中的產品 - 各開發階段

前列腺素D2受體2 (CD294, DP2, PTGDR2等):開發中的產品 - 各治療範圍

前列腺素D2受體2 (CD294, DP2, PTGDR2等):開發中的產品 - 各適應症

前列腺素D2受體2 (CD294, DP2, PTGDR2等):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

前列腺素D2受體2 (CD294, DP2, PTGDR2等):企業開發中的產品

前列腺素D2受體2 (CD294, DP2, PTGDR2等):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

前列腺素D2受體2 (CD294, DP2, PTGDR2等)治療藥的開發企業

  • Allergan Plc
  • Brickell Biotech, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Oxagen Limited
  • Panmira Pharmaceuticals, LLC.
  • Pulmagen Therapeutics LLP
  • Taisho Pharmaceutical Holdings Co., Ltd.

藥物簡介

前列腺素D2受體2 (CD294, DP2, PTGDR2等):暫停中的計劃

前列腺素D2受體2 (CD294, DP2, PTGDR2等):開發中止的產品

前列腺素D2受體2 (CD294, DP2, PTGDR2等):主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0964TDB

Summary:

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation.

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 3 respectively. Report covers products from therapy areas Respiratory, Dermatology, Immunology and Ophthalmology which include indications Asthma, Atopic Dermatitis, Allergic Asthma, Allergic Rhino-Conjunctivitis, Androgenic Alopecia, Allergic Rhinitis, Allergies, Chronic Obstructive Pulmonary Disease (COPD) and Inflammation.

The latest report Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)
  • The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Overview
    • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Boehringer Ingelheim GmbH
    • Brickell Biotech Inc
    • Idorsia Ltd
    • Merck & Co Inc
    • Novartis AG
    • Oxagen Ltd
    • Pulmagen Therapeutics LLP
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles
    • ACT-774312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADC-3680 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADC-7405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADC-9971 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBI-5000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-1060469 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fevipiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-1029 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OC-2417 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setipiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Timapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Products
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products
  • Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma
      • Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma
      • Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers
      • Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis
      • Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
      • Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease
      • Oct 07, 2014: Atopix Therapeutics secures funding from SR One to advance development of CRTH2 antagonists in eosinophilic disease
      • Aug 01, 2014: Pulmagen's lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study
      • Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma
      • Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis
      • May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis
      • Jul 15, 2011: Oxagen Announces Publication Of Phase IIa Asthma Trial Data For OC000459 Which Shows Promise As New Oral Treatment For Asthma And Related Disorders
      • May 23, 2011: Actelion's CRTH2 Antagonist Meets primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis
      • Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma
      • Dec 09, 2009: Oxagen Completes Recruitment Of Patients For Phase IIb Clinical Trial Of OC000459 For Asthma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Allergan Plc, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by Brickell Biotech Inc, H2 2017
  • Pipeline by Idorsia Ltd, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Oxagen Ltd, H2 2017
  • Pipeline by Pulmagen Therapeutics LLP, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top